Ingestible sensors starts to affect health care around 2020
Grader A: partial
Grader B: partial
agrees with A, without seeing its verdict
Audit: confirmed
in the fixed audit sample (D11)
Published: partial
Grader A: partial
The forward-looking product, Proteus ingestible sensor in Abilify MyCite (FDA 2017), saw limited uptake and Proteus went bankrupt in 2020 (assets sold to Otsuka). Niche real use, well below 5%. Capsule endoscopy predates 2012 and is not what the poster forecast.
Test: D37 health: share of relevant patients, providers or procedures using it by 2022 (hit >=5%; partial <5% real use by 2022 or 5% in 2023-2025; miss no real use by 2025); relevant: patients on medication / GI diagnostics
Grader B: partial
Sensor-in-pill adherence (Proteus, Abilify MyCite) reached market but was abandoned (Proteus bankrupt 2020; MyCite discontinued Oct 2024). Capsule endoscopy and motility capsules remain routine niche procedures (over 4 million PillCams sold) but are a small share of GI diagnostics and predate the poster. Real, niche use = partial; reading only the adherence-sensor line would give miss.
Test: D37 health: >=5% of relevant diagnostic procedures or medication-adherence patients use ingestible sensors by 2022 = hit; real but niche use = partial; none or abandoned by 2025 = miss.